Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges.
The development of vaccines for microorganisms and bacterial toxins with the potential to be used as biowarfare and bioterrorism agents is an important component of the US biodefense program. DVC is developing two vaccines, one against inhalational exposure to botulinum neurotoxins A1 and B1 and a second for Yersinia pestis, with the ultimate goal of licensure by the FDA under the Animal Rule. Progress has been made in all technical areas, including manufacturing, nonclinical, and clinical development and testing of the vaccines, and in assay development. The current status of development of these vaccines, and remaining challenges are described in this chapter.
DynPort Vaccine Company LLC, Frederick, MD 21702, USA.
Mary Kate
MK
Hart
George A
GA
Saviolakis
Susan L
SL
Welkos
Robert V
RV
House